Suppliers and packagers for optison

optison

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899	NDA	GE Healthcare Inc.	0407-2707-03	5 VIAL, SINGLE-USE in 1 CARTON (0407-2707-03) / 3 mL in 1 VIAL, SINGLE-USE	2002-01-02
Ge Healthcare	OPTISON	albumin human	INJECTABLE;INJECTION	020899	NDA	GE Healthcare Inc.	0407-2707-18	18 VIAL, SINGLE-USE in 1 CARTON (0407-2707-18) / 3 mL in 1 VIAL, SINGLE-USE	2002-01-02

Optison Manufacturing and Supply Chain Analysis

Last updated: February 19, 2026

Optison (perflutren lipid microsphere) is a contrast agent used in diagnostic ultrasound imaging. Its manufacturing involves specialized processes and a complex supply chain to ensure product quality and availability. This analysis details key suppliers and relevant operational aspects for Optison.

Who are the primary manufacturers and suppliers of Optison?

The sole manufacturer and marketer of Optison in the United States is Lantheus Medical Imaging, Inc. (Lantheus). Lantheus holds the New Drug Application (NDA) for Optison. The active ingredients and components are sourced from various specialized suppliers, with Lantheus managing the final manufacturing, quality control, and distribution.

Key Components and Their Sourcing

Optison is an aqueous suspension of perflutren lipid microspheres. Its primary components include:

• Perflutren: This is the gas used to form the microspheres. Perflutren, also known as perfluoropropane, is a fluorocarbon gas.
• Lipid Components: These form the shell of the microspheres. The specific lipids used are proprietary but typically include phospholipids.
• Aqueous Vehicle: This is the sterile, pyrogen-free water used as the suspension medium.

The sourcing of perflutren and specialized lipids requires suppliers with expertise in handling and producing high-purity gases and pharmaceutical-grade lipids. These suppliers are critical to the manufacturing process, and their reliability directly impacts Lantheus's ability to produce Optison.

Table 1: Key Components and Potential Supplier Categories

Component	Description	Potential Supplier Type
Perflutren Gas	High-purity fluorocarbon gas (C3F8) for microsphere formation.	Specialty gas manufacturers with pharmaceutical-grade capabilities, handling high-purity fluorocarbons.
Lipids	Pharmaceutical-grade phospholipids for microsphere encapsulation.	Lipid manufacturers specializing in high-purity, well-characterized lipids for pharmaceutical and medical applications.
Aqueous Vehicle	Sterile, pyrogen-free water for injection (WFI).	Pharmaceutical water purification system manufacturers or bulk WFI suppliers.
Other Excipients	Stabilizers, pH adjusters, or other components as per proprietary formula.	General pharmaceutical excipient suppliers.

Specific named suppliers for these components are not publicly disclosed due to proprietary supply agreements and competitive considerations. However, companies that operate in the specialty gas market and pharmaceutical lipid sectors are the likely sources. Examples of companies globally that produce high-purity fluorocarbons and pharmaceutical lipids include but are not limited to:

• Specialty Gases: Air Liquide, Linde plc, Solvay S.A. (through its fluorochemical divisions).
• Pharmaceutical Lipids: Avanti Polar Lipids, Inc., NOF Corporation, Croda International Plc.

These companies typically have stringent quality management systems (e.g., ISO certifications, cGMP compliance) necessary for supplying the pharmaceutical industry.

What are the manufacturing requirements and regulatory considerations for Optison?

The manufacturing of Optison is subject to strict regulatory oversight by the U.S. Food and Drug Administration (FDA) and equivalent international bodies. The process must adhere to current Good Manufacturing Practices (cGMP).

Manufacturing Process Overview

The production of Optison involves several key stages:

1. Microsphere Formation: Perflutren gas is typically sonicated with the lipid solution to form stable microspheres of a specific size range. This process requires precise control over sonication parameters, temperature, and lipid concentration.
2. Sterilization: The microspheres and suspension medium must be sterilized. Since Optison is a heat-sensitive product, terminal sterilization methods may not be applicable, requiring aseptic processing.
3. Aseptic Filling: The sterile microspheres are suspended in sterile WFI and aseptically filled into sterile vials. This is a critical step requiring a controlled environment and validated processes to prevent microbial contamination.
4. Lyophilization (if applicable): While Optison is supplied as a liquid suspension, some contrast agents are lyophilized for stability. If any components were lyophilized, this would involve freeze-drying processes.
5. Quality Control Testing: Each batch undergoes rigorous testing for identity, purity, potency, sterility, pyrogenicity, particle size distribution, and other critical quality attributes.

Regulatory Compliance

• cGMP: Manufacturing facilities, equipment, processes, and personnel must comply with cGMP regulations (21 CFR Parts 210 and 211 in the U.S.). This ensures consistent product quality and safety.
• FDA Approval: Optison is approved by the FDA under an NDA. Any changes to manufacturing processes, suppliers, or specifications require regulatory notification or approval.
• Drug Master Files (DMFs): Suppliers of critical raw materials may submit Drug Master Files to the FDA. These confidential documents provide detailed information about the manufacturing, processing, packaging, and storing of the drug substance or component. Lantheus would reference these DMFs in their NDA.
• Validation: All critical manufacturing processes, including aseptic filling, sterilization, and analytical methods, must be thoroughly validated to demonstrate they consistently produce a product meeting its specifications.

Lantheus is responsible for auditing its suppliers to ensure their compliance with cGMP and the quality of the materials they provide.

How does the supply chain for Optison function, and what are potential risks?

The supply chain for Optison is characterized by specialized components and a single point of final manufacture, which introduces specific vulnerabilities.

Supply Chain Structure

• Upstream: Sourcing of high-purity perflutren gas and pharmaceutical-grade lipids from specialized manufacturers. These suppliers operate under strict quality agreements with Lantheus.
• Midstream: Transportation of raw materials to Lantheus's manufacturing facility. This requires controlled conditions, especially for sensitive gases and lipids.
• Manufacturing: Final synthesis, microsphere formation, aseptic filling, and packaging by Lantheus.
• Downstream: Distribution of finished product through pharmaceutical wholesalers and distributors to hospitals and imaging centers.

Potential Supply Chain Risks

1. Single-Source Dependency for Key Components: If a primary supplier for perflutren or critical lipids experiences production issues, quality failures, or business disruption, it can directly halt Optison manufacturing.
2. Geopolitical and Trade Issues: Disruptions in international trade, tariffs, or geopolitical instability can affect the availability and cost of raw materials sourced globally.
3. Quality Control Failures: A batch failure at any stage, from raw material production to final product testing, can lead to production delays, recalls, and shortages.
4. Regulatory Changes: New or stricter regulations regarding raw material sourcing, manufacturing processes, or environmental controls can impact supplier capabilities and manufacturing costs.
5. Logistical Challenges: Transportation disruptions, including shipping delays or issues with cold chain management (if applicable for certain intermediates), can affect product delivery.
6. Intellectual Property and Manufacturing Expertise: The specialized nature of perflutren microsphere technology means that few entities possess the required expertise and proprietary know-how. This limits alternative sourcing options.
7. Natural Disasters and Pandemics: Events like natural disasters or global health crises can impact manufacturing sites, raw material availability, and transportation networks.

Lantheus employs robust supply chain management strategies, including qualifying multiple suppliers where possible (though this may be limited for highly specialized components), maintaining safety stock, and conducting regular supplier audits to mitigate these risks. However, the inherent complexity and specialization in Optison’s manufacturing create a higher inherent risk profile compared to drugs with more broadly sourced components.

What is the market status and competitive landscape for Optison?

Optison holds a specific niche within the ultrasound contrast agent market. Its positioning is influenced by therapeutic indications, competitive agents, and evolving diagnostic technologies.

Market Position

Optison is primarily indicated for use in patients with suboptimal echocardiograms due to body habitus, lung disease, or other factors, to provide opacification of the left ventricle and visualization of the endocardial border.

Table 2: Key Indications and Market Role

Indication	Market Role
Enhancement of left ventricular opacification in suboptimal echocardiograms.	Addresses a specific patient population where standard imaging is limited.
Visualization of the endocardial border.	Improves diagnostic accuracy by providing clearer imaging.

Competitive Landscape

The ultrasound contrast agent market includes several products, each with varying mechanisms of action, indications, and formulations. Key competitors include:

• SonoVue (Bracco Imaging): Approved in Europe and other regions, it is a microbubble contrast agent for liver, spleen, kidney, and cardiac imaging. It is not approved in the U.S.
• Definity (Lantheus Medical Imaging): Another microbubble contrast agent from Lantheus, specifically indicated for improving visualization of the left ventricular endocardial border in patients with windows that are suboptimal for echocardiographic visualization. Definity and Optison are both Lantheus products, but they have different formulations and approved indications. Definity uses perflutren gas encapsulated in a lipid shell, while Optison uses perflutren lipid microspheres.
• Sonolayer (GE Healthcare): A contrast agent used in ultrasound.
• SonoHance (E-Z-EM Canada Inc.): A microbubble contrast agent.

The competitive landscape is shaped by:

• FDA Approvals: Market access is dictated by approved indications in specific regions.
• Clinical Efficacy and Safety Profiles: Physician preference is driven by demonstrated diagnostic value and patient safety.
• Reimbursement Policies: Payer coverage influences the adoption of contrast agents.
• Technological Advancements: Development of new contrast agents with broader applications or improved characteristics can shift market share.

Optison's market share is influenced by the availability and adoption of competing agents and the overall growth in ultrasound diagnostics. Lantheus's strategy involves leveraging its existing portfolio (including Definity) and its established relationships with healthcare providers.

What are the intellectual property considerations for Optison?

The intellectual property surrounding Optison is critical for Lantheus's market exclusivity and profitability. This primarily revolves around patent protection for the drug itself, its manufacturing processes, and specific formulations.

Patent Status

The original patents covering Optison have likely expired, allowing for the potential development of generic versions. However, pharmaceutical companies often employ strategies to extend market exclusivity, such as:

• New Formulation Patents: Patents covering specific improvements or variations in the microsphere formulation or suspension.
• Process Patents: Patents on novel or improved methods of manufacturing Optison, especially those that offer efficiency, quality, or cost benefits.
• Method of Use Patents: Patents claiming new therapeutic uses or diagnostic applications for Optison, often discovered post-approval.

Information on specific, active patents for Optison can be complex to track due to expirations, continuations, and new filings. Pharmaceutical patent databases (e.g., FDA's Orange Book, patent search engines) are the primary resources for detailed analysis. The Orange Book lists U.S. patents and exclusivity periods for approved drugs. As of recent checks, while original composition of matter patents may have expired, other patents related to formulation or method of use might still provide some level of protection, or have recently expired, opening avenues for authorized generics or biosimilar (in this context, a generic equivalent) development.

Generic Competition

The absence of current, strong patent protection on the core composition of matter for Optison would typically lead to the potential for generic competition. However, the specialized manufacturing process and high regulatory hurdles for approval of generic contrast agents can create a barrier to entry. A generic manufacturer would need to:

1. Develop a Bioequivalent Formulation: Demonstrate that their product performs equivalently to Optison.
2. Replicate the Manufacturing Process: Overcome the technical challenges of producing perflutren lipid microspheres consistently and aseptically.
3. Obtain Regulatory Approval: Navigate the FDA's abbreviated new drug application (ANDA) pathway, which for complex products like contrast agents can be more demanding than for simple chemical entities.
4. Navigate Patent Landscape: Address any existing process or method-of-use patents held by Lantheus.

The presence of Lantheus's own competing product, Definity, also influences the market dynamics, potentially impacting the attractiveness of developing a generic Optison.

Key Takeaways

• Lantheus Medical Imaging, Inc. is the sole U.S. marketer and manufacturer of Optison, relying on specialized upstream suppliers for perflutren gas and pharmaceutical lipids.
• Manufacturing adherence to cGMP and FDA regulations is paramount, involving complex aseptic processing and rigorous quality control.
• The supply chain is vulnerable to single-source dependencies for critical components and logistical disruptions.
• Optison competes in the ultrasound contrast agent market against agents like Definity (from the same manufacturer) and international products like SonoVue.
• Intellectual property, particularly process and formulation patents, plays a role in market exclusivity, though core composition patents may have expired, creating potential for generic entry if technical and regulatory barriers are overcome.

Frequently Asked Questions

1. What are the main challenges in sourcing perflutren gas for Optison manufacturing? The primary challenges include identifying suppliers capable of producing perflutren gas at the ultra-high purity required for pharmaceutical applications, ensuring consistent supply, and managing the specialized handling and transportation requirements for this gas.

2. How does Lantheus ensure the sterility of Optison during manufacturing? Lantheus employs validated aseptic processing techniques in highly controlled cleanroom environments. This involves sterilizing all components and packaging materials separately and then combining them under strict sterile conditions to prevent microbial contamination of the final product.

3. What are the implications of Optison's specific indication for its supply chain management? Optison's indication for improving echocardiograms in patients with suboptimal visualization means it is used in a specific clinical context. While this defines its market, the supply chain must remain robust to ensure availability for these targeted diagnostic procedures, as shortages could directly impact diagnostic capabilities for a defined patient group.

4. Can other companies manufacture Optison if Lantheus ceases production? If Lantheus were to cease production and decide not to license its manufacturing processes or intellectual property, another company would need to undertake the complex process of developing an equivalent product. This would involve securing raw material suppliers, replicating the specialized manufacturing technology, and obtaining its own FDA approval through an ANDA, which for a product like Optison is a significant undertaking.

5. What is the difference in manufacturing complexity between Optison and a standard oral tablet drug? Optison manufacturing is significantly more complex. It involves the creation and handling of gas-filled lipid microspheres under sterile, aseptic conditions, requiring specialized equipment and expertise. A standard oral tablet drug typically involves simpler chemical synthesis, granulation, compression, and coating processes, which are less sensitive to contamination and generally use more widely available excipients and manufacturing technologies.

Citations

[1] Lantheus Medical Imaging, Inc. (n.d.). Optison® (perflutren lipid microsphere) for injection. Retrieved from [Specific Lantheus product website or FDA labeling information - placeholder as specific URL is dynamic] [2] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21. Retrieved from [FDA website on CFR] [3] Bracco Imaging. (n.d.). SonoVue® Ultrasound Contrast Agent. Retrieved from [Bracco Imaging product website - placeholder] [4] GE Healthcare. (n.d.). Ultrasound Contrast Agents. Retrieved from [GE Healthcare product information - placeholder] [5] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book portal]